RAMP1

Summary

RAMP1 (receptor activity modifying protein 1, HGNC:9843) is a protein-coding gene on chromosome 2q37.3, encoding Receptor activity-modifying protein 1 (O60894). Accessory protein that interacts with and modulates the function of G-protein coupled receptors including calcitonin gene-related peptide type 1 receptor (CALCRL) and calcitonin receptor (CALCR).

The protein encoded by this gene is a member of the RAMP family of single-transmembrane-domain proteins, called receptor (calcitonin) activity modifying proteins (RAMPs). RAMPs are type I transmembrane proteins with an extracellular N terminus and a cytoplasmic C terminus. RAMPs are required to transport calcitonin-receptor-like receptor (CRLR) to the plasma membrane. CRLR, a receptor with seven transmembrane domains, can function as either a calcitonin-gene-related peptide (CGRP) receptor or an adrenomedullin receptor, depending on which members of the RAMP family are expressed. In the presence of this (RAMP1) protein, CRLR functions as a CGRP receptor. The RAMP1 protein is involved in the terminal glycosylation, maturation, and presentation of the CGRP receptor to the cell surface. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 10267 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 40 total
• Druggable target: yes — 10 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005855

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9843
Approved symbol	RAMP1
Name	receptor activity modifying protein 1
Location	2q37.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000132329
Ensembl biotype	protein_coding
OMIM	605153
Entrez	10267

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000254661, ENST00000403885, ENST00000404910, ENST00000409726, ENST00000884470, ENST00000884471, ENST00000951440

RefSeq mRNA: 2 — MANE Select: NM_005855 NM_001308353, NM_005855

CCDS: CCDS2522, CCDS77546

Canonical transcript exons

ENST00000254661 — 3 exons

Exon	Start	End
ENSE00001073872	237859623	237859727
ENSE00001073873	237911528	237912106
ENSE00003594791	237877224	237877362

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 99.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.6863 / max 363.6931, expressed in 929 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26306	8.5133	885
26303	0.6372	186
26305	0.3102	130
26304	0.1019	38
26302	0.0761	20
26301	0.0476	21

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of uterus	UBERON:0009853	99.55	gold quality
ascending aorta	UBERON:0001496	99.31	gold quality
thoracic aorta	UBERON:0001515	99.30	gold quality
endocervix	UBERON:0000458	99.18	gold quality
descending thoracic aorta	UBERON:0002345	99.18	gold quality
right coronary artery	UBERON:0001625	99.12	gold quality
aorta	UBERON:0000947	98.83	gold quality
left uterine tube	UBERON:0001303	98.80	gold quality
apex of heart	UBERON:0002098	98.63	gold quality
popliteal artery	UBERON:0002250	98.55	gold quality
tibial artery	UBERON:0007610	98.55	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.46	gold quality
mucosa of stomach	UBERON:0001199	98.44	gold quality
lower esophagus	UBERON:0013473	98.34	gold quality
myometrium	UBERON:0001296	98.31	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.19	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.18	gold quality
body of pancreas	UBERON:0001150	98.16	gold quality
right atrium auricular region	UBERON:0006631	98.12	gold quality
heart left ventricle	UBERON:0002084	97.88	gold quality
cardiac ventricle	UBERON:0002082	97.67	gold quality
nucleus accumbens	UBERON:0001882	97.56	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.49	gold quality
left coronary artery	UBERON:0001626	97.38	gold quality
cardiac atrium	UBERON:0002081	97.22	gold quality
amygdala	UBERON:0001876	97.17	gold quality
coronary artery	UBERON:0001621	97.05	gold quality
gastrocnemius	UBERON:0001388	96.97	gold quality
right frontal lobe	UBERON:0002810	96.92	gold quality
caudate nucleus	UBERON:0001873	96.87	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	2092.41
E-MTAB-6701	yes	1335.61
E-HCAD-24	yes	1059.36
E-HCAD-36	yes	993.18
E-MTAB-9906	yes	561.89
E-GEOD-125970	yes	296.81
E-CURD-84	yes	236.19
E-HCAD-1	yes	31.99
E-HCAD-6	yes	30.32
E-MTAB-6678	yes	29.91
E-MTAB-8142	yes	27.98
E-MTAB-5061	yes	18.83
E-HCAD-25	yes	17.29
E-CURD-112	yes	5.25
E-HCAD-10	yes	4.10

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NKX3-1

miRNA regulators (miRDB)

15 targeting RAMP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6881-5P	98.16	67.38	665
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-6842-3P	98.07	66.33	1325
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4430	97.47	65.61	1813
HSA-MIR-4474-3P	96.97	65.87	870
HSA-MIR-6890-5P	92.89	65.83	442

Literature-anchored findings (GeneRIF, showing 40)

• Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells (PMID:11693189)
• Co-expression of RAMP1 and CRLR reconstituted a CGRP receptor that was able to activate the pheromone-signaling pathway with pharmacological properties similar to those observed previously in mammalian cells. (PMID:11733510)
• Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. (PMID:11847213)
• The CGRP receptor components, RAMP1 and CRLR, are down-regulated during myeloid differentiation of CD34+ cells, and CGRP receptor selectively promotes the development of CFU-GM. (PMID:11937264)
• results show the presence of calcitonin receptor-like receptor and receptor activity-modifying proteins in middle meningeal, middle cerebral, pial, and superficial temporal vessels (PMID:11973435)
• Co-expression of calcitonin receptors (CT) lacking a portion of domain 1 with receptor activity-modifying protein (RAMP) 1, 2, or 3 appears to produce functional CT-(8-32)-sensitive adrenomedullin receptors. (PMID:12565884)
• The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function (PMID:12574158)
• identification of domains responsible for agonist binding specificity (PMID:12684503)
• TNF-alpha induced time- and dose-dependent decreases in the expression of RAMP1 mRNA in cultured human coronary artery smooth muscle cells, thereby diminishing AM-evoked cAMP production (PMID:15245870)
• Data found that expressions of RAMP1, RAMP2 and RAMP3 mRNAs increased with the worsening of heart function, but the expressions of RAMP1 and RAMP2 mRNA decreased at level IV of heart failure. (PMID:15300632)
• calcitonin receptor-like receptor heterodimer with RAMP1 yields a calcitonin gene-related peptide receptor (PMID:15613468)
• This study reveals important functionality of the RAMP C-terminal domain and identifies key differences in the role of the RAMP C terminus for calcitonin receptor versus calcitonin receptor-like receptor-based receptors. (PMID:16912219)
• CLR and RAMP1 traffic from endosomes to lysosomes by ubiquitin-independent mechanisms, where they are degraded at different rates (PMID:17310067)
• RAMP1 interacts with tubulin. (PMID:17493758)
• Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor and RAMP1. (PMID:17785463)
• We did not observe any difference in mRNA for CL-R and RAMPs in arteries from patients with hemorrhagic stroke, arteriosclerosis and acute myocardial infarction when compared to patients without these diagnoses (PMID:18198792)
• RAMP1 may be strongly considered as a candidate gene for migraine. (PMID:18240900)
• Identification of RAMP1 residues important for calcitonin gene-related peptide are reported. (PMID:18593822)
• the crystal structure of the extracellular domain of human RAMP1 at 2.4 A resolution was determined. (PMID:18725456)
• The T-A-C haplotype is a genetic marker for cerebral infarction, and RAMP1 is associated with increased susceptibility to cerebral infarction. (PMID:19710695)
• RAMP1 overexpression attenuates Ang-II-induced hypertension and induces a protective change in cardiovascular autonomic regulation (PMID:20100989)
• These data for the first time pinpoint a specific RAMP1 residue important for both antagonist and agonist potency and are consistent with the N-terminal domain of RAMP1 forming the binding pocket interface with calcitonin receptor-like receptor. (PMID:20188075)
• lower expression in bronchial biopsies from subjects with asthma (PMID:20933260)
• The present finding demonstrated that RAMP1 immunoreactivity was localized in many neurons and phenopalatine ganglion. (PMID:22208649)
• CLR and RAMP1 co-localize in the enteric nervous system of human stomach, ileum, and colon, and are in close proximity to their ligands CGRP and IMD (PMID:22484227)
• RAMP1 overexpression enhances the promoting effect that exogenous CGRP has on osteogenic differentiation (PMID:22949393)
• No significant association of the tested SNPs of the RAMP1 gene were found with migraine susceptibility. (PMID:23237777)
• multiple NKX3.1 binding sites were found in the RAMP1 locus in human prostate cancer cells and in the normal mouse prostate. (PMID:23867798)
• A novel functional role for RAMP1 in regulation of CaSR signalling in addition to its known role in receptor trafficking, is reported. (PMID:24454825)
• RAMP1 rs7590387 has a role in the transformation of episodic migraine into medication overuse headache. (PMID:25881990)
• Data suggest that ligand binding of a G protein-coupled receptor (GPCR) may inform drug development targeting calcitonin receptor-like receptor (CLR):receptor activity-modifying proteins RAMP1/2 complexes. (PMID:25982113)
• Evidence that DNA methylation at RAMP1 gene promoter plays a role in migraine was described. (PMID:26501962)
• T-A-T RAMP1 gene haplotype might have utility as a genetic marker for Essential Hypertension and that the RAMP1 gene may be associated with increased susceptibility to Essential Hypertension in a Japanese population. (PMID:28181496)
• Data suggest CGRP receptor (CGRPR) ECL2 (extracellular loop 2 domain) enables interaction with N-terminal residues of CGRP; this provides evidence for dual involvement of ECL2 in two-domain binding model of CGRP/CGRPR interaction; CGRPR is obligate heterodimer of CLR/RAMP1. (CGRP = calcitonin gene-related peptide; CLR = calcitonin receptor-like receptor; RAMP1 = receptor [calcitonin] activity modifying protein 1) (PMID:28691801)
• in nestin/hRAMP1 transgenic mice, hypertension caused by Ang II or phenylephrine was greatly attenuated, and associated autonomic dysregulation and increased sympathetic vasomotor tone were diminished or abolished. (PMID:29297736)
• structure of the human CGRP receptor in complex with CGRP and the Gs-protein heterotrimer at 3.3 A global resolution, determined by Volta phase-plate cryo-electron microscopy (PMID:30209400)
• Based on the finding that an acylated chimeric ADM/ADM2 analog potently stimulates CLR/RAMP1 and 2 signaling, we hypothesized that the binding domain of this analog could have potent inhibitory activity on CLR/RAMP receptors. (PMID:31150417)
• Structure and dynamics of the CGRP receptor in apo and peptide-bound forms. (PMID:33602864)
• Peptide ligand interaction with maltose-binding protein tagged to the calcitonin gene-related peptide receptor: The inhibitory role of receptor N-glycosylation. (PMID:35007660)
• Involvement of RAMP1/p38MAPK signaling pathway in osteoblast differentiation in response to mechanical stimulation: a preliminary study. (PMID:38825686)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ramp1	ENSDARG00000056704
mus_musculus	Ramp1	ENSMUSG00000034353
rattus_norvegicus		ENSRNOG00000089232

Paralogs (2): RAMP3 (ENSG00000122679), RAMP2 (ENSG00000131477)

Protein

Protein identifiers

Receptor activity-modifying protein 1 — O60894 (reviewed: O60894)

Alternative names: Calcitonin-receptor-like receptor activity-modifying protein 1

All UniProt accessions (2): O60894, E9PC20

UniProt curated annotations — full annotation on UniProt →

Function. Accessory protein that interacts with and modulates the function of G-protein coupled receptors including calcitonin gene-related peptide type 1 receptor (CALCRL) and calcitonin receptor (CALCR). Required for the transport of CALCRL to the plasma membrane. Together with CALCRL, form the receptor complex for the calcitonin gene-related peptides CGRP1/CALCA and CGRP2/CALCB. Together with CALCR, form the AMYR1 receptor complex for amylin/IAPP and CGRP1/CALCA.

Subunit / interactions. Heterodimer of CALCRL and RAMP1; the interaction induces allosteric modulation of CALCRL function and CGRP1/CALCA and CGRP2/CALCB ligand specificity. Heterodimer of CALCR and RAMP1; interaction forms the AMYR1 receptor complex for amylin/IAPP and CGRP1/CALCA ligands.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in many tissues including the uterus, bladder, brain, pancreas and gastro-intestinal tract.

Similarity. Belongs to the RAMP family.

RefSeq proteins (2): NP_001295282, NP_005846* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006985	RAMP	Family
IPR038126	RAMP_sf	Homologous_superfamily

Pfam: PF04901

UniProt features (19 total): helix 7, strand 3, disulfide bond 3, topological domain 2, signal peptide 1, chain 1, turn 1, transmembrane region 1

Structure

Experimental structures (PDB)

26 structures.

PDB	Method	Resolution (Å)
6ZHO	X-RAY DIFFRACTION	1.6
8AX7	X-RAY DIFFRACTION	1.65
6ZIS	X-RAY DIFFRACTION	1.73
7P0F	X-RAY DIFFRACTION	1.85
8AX6	X-RAY DIFFRACTION	1.9
6D1U	X-RAY DIFFRACTION	2.05
3N7S	X-RAY DIFFRACTION	2.1
7TYF	ELECTRON MICROSCOPY	2.2
9BP3	ELECTRON MICROSCOPY	2.2
7P0I	X-RAY DIFFRACTION	2.3
2YX8	X-RAY DIFFRACTION	2.4
9AUC	ELECTRON MICROSCOPY	2.4
4RWG	X-RAY DIFFRACTION	2.44
6UMG	X-RAY DIFFRACTION	2.7
8AX5	X-RAY DIFFRACTION	2.75
3N7P	X-RAY DIFFRACTION	2.8
5V6Y	X-RAY DIFFRACTION	2.8
3N7R	X-RAY DIFFRACTION	2.9
7TYW	ELECTRON MICROSCOPY	3
9UWQ	ELECTRON MICROSCOPY	3.1
7KNT	ELECTRON MICROSCOPY	3.15
9BLW	ELECTRON MICROSCOPY	3.2
9MM5	ELECTRON MICROSCOPY	3.26
6E3Y	ELECTRON MICROSCOPY	3.3
7KNU	ELECTRON MICROSCOPY	3.49
9MNI	ELECTRON MICROSCOPY	4.06

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60894-F1	89.95	0.75

Antibody-complex structures (SAbDab): 6 — 6E3Y, 6UMG, 7TYF, 7TYW, 9AUC, 9BLW

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 27–82, 40–72, 57–104

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-418555	G alpha (s) signalling events
R-HSA-419812	Calcitonin-like ligand receptors

MSigDB gene sets: 362 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, VERHAAK_AML_WITH_NPM1_MUTATED_DN, BENPORATH_ES_WITH_H3K27ME3, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_MONOATOMIC_CATION_TRANSPORT, PATIL_LIVER_CANCER, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_GLYCOPROTEIN_METABOLIC_PROCESS

GO Biological Process (15): angiogenesis (GO:0001525), calcium ion transport (GO:0006816), intracellular protein transport (GO:0006886), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), regulation of G protein-coupled receptor signaling pathway (GO:0008277), positive regulation of glycoprotein biosynthetic process (GO:0010560), protein transport (GO:0015031), receptor internalization (GO:0031623), cellular response to hormone stimulus (GO:0032870), protein localization to plasma membrane (GO:0072659), amylin receptor signaling pathway (GO:0097647), amylin receptor 1 signaling pathway (GO:0150059), calcitonin gene-related peptide receptor signaling pathway (GO:1990408), obsolete positive regulation of protein glycosylation (GO:0060050)

GO Molecular Function (5): calcitonin gene-related peptide receptor activity (GO:0001635), coreceptor activity (GO:0015026), amylin receptor activity (GO:0097643), calcitonin gene-related peptide binding (GO:1990407), protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), cell surface (GO:0009986), signaling receptor complex (GO:0043235), CGRP receptor complex (GO:1990406), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
GPCR downstream signalling	1
Class B/2 (Secretin family receptors)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
calcitonin family receptor signaling pathway	2
calcitonin family receptor activity	2
cellular anatomical structure	2
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
metal ion transport	1
protein transport	1
intracellular transport	1
G protein-coupled receptor activity	1
signal transduction	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
G protein-coupled receptor signaling pathway	1
regulation of signal transduction	1
glycoprotein biosynthetic process	1
positive regulation of macromolecule biosynthetic process	1
regulation of glycoprotein biosynthetic process	1
positive regulation of glycoprotein metabolic process	1
transport	1
establishment of protein localization	1
receptor-mediated endocytosis	1
response to hormone	1
cellular response to chemical stimulus	1
cellular response to endogenous stimulus	1
protein localization to membrane	1
protein localization to cell periphery	1
amylin receptor signaling pathway	1
signaling receptor activity	1
calcitonin family binding	1
binding	1
membrane	1
cell periphery	1
protein-containing complex	1
calcitonin family receptor complex	1

Protein interactions and networks

STRING

622 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAMP1	CALCR	P30988	999
RAMP1	CALCRL	Q16602	999
RAMP1	CRCP	O75575	981
RAMP1	IAPP	P10997	980
RAMP1	ADM	P35318	976
RAMP1	CALCB	P10092	965
RAMP1	CALCA	P01258	929
RAMP1	ADM2	Q7Z4H4	922
RAMP1	VIPR1	P32241	766
RAMP1	VIPR2	P41587	748
RAMP1	TAC1	P20366	700
RAMP1	CASR	P41180	696
RAMP1	RAMP2	O60895	653
RAMP1	RAMP3	O60896	651
RAMP1	TACR1	P25103	618

IntAct

396 interactions, top by confidence:

A	B	Type	Score
CALCRL	RAMP1	psi-mi:“MI:0407”(direct interaction)	0.810
RAMP1	CALCRL	psi-mi:“MI:0407”(direct interaction)	0.810
RAMP1	CALCRL	psi-mi:“MI:0915”(physical association)	0.810
CALCA	RAMP1	psi-mi:“MI:0915”(physical association)	0.610
NKG7	RAMP1	psi-mi:“MI:0915”(physical association)	0.560
MAL	RAMP1	psi-mi:“MI:0915”(physical association)	0.560
MS4A13	RAMP1	psi-mi:“MI:0915”(physical association)	0.560
RAMP1	NKG7	psi-mi:“MI:0915”(physical association)	0.560
RAMP1	MAL	psi-mi:“MI:0915”(physical association)	0.560
RAMP1	MS4A13	psi-mi:“MI:0915”(physical association)	0.560
ACKR3	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADGRE5	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADGRG3	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADGRG5	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADORA1	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
RAMP1	ADORA2A	psi-mi:“MI:0915”(physical association)	0.400
ADORA2B	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADRB1	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
ADRB2	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
AVPR1A	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
AVPR1B	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
BDKRB1	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
BDKRB2	RAMP1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (46): RAMP1 (Synthetic Growth Defect), RAMP1 (Synthetic Growth Defect), CALCRL (Affinity Capture-Luminescence), CALCRL (Reconstituted Complex), RAMP1 (Affinity Capture-RNA), RAMP1 (Reconstituted Complex), RAMP1 (Reconstituted Complex), RAMP1 (Reconstituted Complex), RAMP1 (Reconstituted Complex), RAMP1 (Affinity Capture-Western), RAMP1 (Two-hybrid), MAL (Two-hybrid), MS4A13 (Two-hybrid), RAMP1 (Reconstituted Complex), RAMP1 (Co-localization)

ESM2 similar proteins: A7MBM2, E9PY61, O00391, O08542, O60894, O60895, O76095, O77049, O88824, P52798, Q15904, Q16586, Q5Q0T9, Q5RJL6, Q641Q3, Q6IUU3, Q6P5F7, Q6PRD1, Q6UWJ8, Q6ZVN8, Q6ZVW7, Q7TQ32, Q80YF6, Q864V4, Q867C0, Q86WC4, Q8BGT0, Q8BH06, Q8BND5, Q8C1Q4, Q8K4C2, Q8N271, Q8N7M5, Q8NAC3, Q8R4C4, Q8R4C5, Q8R4C6, Q8VE43, Q91ZV8, Q96F46

Diamond homologs: O60894, O60896, Q7YS88, Q867C0, Q8R4C4, Q8R4C6, Q9JJ73, Q9JJ74, Q9WTJ5, Q9WUP1, Q8R4C5, Q9JHJ1, Q9WUP0, O60895

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RAMP1	“form complex”	“Amylin receptor 1 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 165 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Amine ligand-binding receptors	20	50.1×	1e-29
Class A/1 (Rhodopsin-like receptors)	58	31.2×	6e-73
GPCR ligand binding	55	25.6×	2e-63
Peptide ligand-binding receptors	44	23.6×	2e-48
G alpha (q) signalling events	50	20.8×	4e-52
G alpha (s) signalling events	32	17.0×	1e-29
GPCR downstream signalling	53	16.7×	2e-50
Chemokine receptors bind chemokines	12	16.3×	1e-10

GO biological processes:

GO term	Partners	Fold	FDR
activation of adenylate cyclase activity	8	55.1×	3e-11
complement receptor mediated signaling pathway	7	48.2×	2e-09
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	22	42.1×	1e-28
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	30	40.3×	7e-39
dendritic cell chemotaxis	6	36.5×	4e-07
phospholipase C-activating G protein-coupled receptor signaling pathway	43	34.7×	3e-53
vasoconstriction	6	32.6×	7e-07
positive regulation of cytosolic calcium ion concentration	45	32.3×	4e-54

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	6
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

898 predictions. Top by Δscore:

Variant	Effect	Δscore
2:237859725:TGGG:T	donor_loss	1.0000
2:237859726:GG:G	donor_gain	1.0000
2:237859726:GGGT:G	donor_loss	1.0000
2:237859727:GG:G	donor_gain	1.0000
2:237859728:G:GA	donor_loss	1.0000
2:237859728:G:GG	donor_gain	1.0000
2:237859729:T:G	donor_loss	1.0000
2:237859732:G:GG	donor_gain	1.0000
2:237859723:CCTGG:C	donor_gain	0.9900
2:237859725:TGG:T	donor_gain	0.9900
2:237859726:GGG:G	donor_gain	0.9900
2:237877222:A:AG	acceptor_gain	0.9900
2:237877223:G:GG	acceptor_gain	0.9900
2:237877359:TCAGG:T	donor_loss	0.9900
2:237877363:G:T	donor_loss	0.9900
2:237877364:T:A	donor_loss	0.9900
2:237911523:CGCA:C	acceptor_loss	0.9900
2:237911524:GCA:G	acceptor_loss	0.9900
2:237911525:CA:C	acceptor_loss	0.9900
2:237911526:A:AG	acceptor_gain	0.9900
2:237911526:AG:A	acceptor_gain	0.9900
2:237911527:G:GG	acceptor_gain	0.9900
2:237911527:G:GT	acceptor_loss	0.9900
2:237911527:GG:G	acceptor_gain	0.9900
2:237911527:GGA:G	acceptor_gain	0.9900
2:237859724:CTGG:C	donor_gain	0.9800
2:237859730:GA:G	donor_gain	0.9800
2:237877223:GCCC:G	acceptor_gain	0.9800
2:237911525:CAGG:C	acceptor_gain	0.9800
2:237911526:AGGA:A	acceptor_gain	0.9800

AlphaMissense

958 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:237877302:T:G	F44C	0.984
2:237877301:T:C	F44L	0.983
2:237877303:C:A	F44L	0.983
2:237877303:C:G	F44L	0.983
2:237877348:G:C	W59C	0.980
2:237877348:G:T	W59C	0.980
2:237911637:T:C	F101L	0.980
2:237911638:T:G	F101C	0.980
2:237911639:C:A	F101L	0.980
2:237911639:C:G	F101L	0.980
2:237911588:G:C	W84C	0.970
2:237911588:G:T	W84C	0.970
2:237911638:T:C	F101S	0.962
2:237877302:T:C	F44S	0.958
2:237877340:T:A	C57S	0.957
2:237877341:G:C	C57S	0.957
2:237911637:T:A	F101I	0.950
2:237911647:G:A	C104Y	0.939
2:237877339:G:C	W56C	0.933
2:237877339:G:T	W56C	0.933
2:237911583:T:C	F83L	0.932
2:237911585:C:A	F83L	0.932
2:237911585:C:G	F83L	0.932
2:237911614:T:G	F93C	0.930
2:237911637:T:G	F101V	0.930
2:237911613:T:C	F93L	0.926
2:237911615:C:A	F93L	0.926
2:237911615:C:G	F93L	0.926
2:237877341:G:A	C57Y	0.925
2:237911552:C:G	C72W	0.924

dbSNP variants (sampled 300 via entrez): RS1000069537 (2:237860308 A>G), RS1000092442 (2:237865938 G>A), RS1000126621 (2:237903059 A>C), RS1000155108 (2:237876597 G>A), RS1000213712 (2:237884991 C>T), RS1000270684 (2:237879250 G>A), RS1000300869 (2:237895615 G>A), RS1000321310 (2:237881750 G>A,C), RS1000322604 (2:237879455 G>T), RS1000346965 (2:237871280 G>A,T), RS1000415620 (2:237912388 C>T), RS1000471340 (2:237897732 C>G,T), RS1000488882 (2:237893478 T>C), RS1000495195 (2:237885718 C>G,T), RS1000565652 (2:237884844 G>C)

Disease associations

OMIM: gene MIM:605153 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_366	Obesity-related traits	8.000000e-06
GCST004523_9	Resting metabolic rate	8.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0008004	resting metabolic rate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2107838 (PROTEIN COMPLEX), CHEMBL2111189 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

10 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 3,069 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL2103758	PRAMLINTIDE	4	883
CHEMBL2364638	UBROGEPANT	4	428
CHEMBL3989767	CALCITONIN SALMON	4	666
CHEMBL3991065	ATOGEPANT	4	251
CHEMBL236593	TELCAGEPANT	3	254
CHEMBL4802169	CAGRILINTIDE	3
CHEMBL1910936	MK3207	2	163
CHEMBL207197	OLCEGEPANT	2	347
CHEMBL3334624	BI-44370	2	62
CHEMBL4635331	HTL-0022562	1	15

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6431564	RAMP1		0.00	0
rs13386048	RAMP1		0.00	0
rs12465864	RAMP1		0.00	0

Binding affinities (BindingDB)

14 measured of 14 human assays (14 total across all organisms); most potent 14 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	KI	0.02 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-1-[[(2S)-3-[1-[2-(dimethylamino)ethyl]piperidin-4-yl]-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]-3-(7-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-1-oxopropan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	KI	0.025 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(7-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4’-piperidine]-1’-carboxamide	KI	0.032 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-(1-propylpiperidin-4-yl)-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxoquinolin-3-ylidene)piperidine-1-carboxamide	KI	0.04 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-1-[[(2S)-3-(1-ethylpiperidin-4-yl)-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl]-4-(2-oxoquinolin-3-ylidene)piperidine-1-carboxamide	KI	0.04 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	KI	0.04 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxoquinolin-3-ylidene)piperidine-1-carboxamide	KI	0.063 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide	KI	0.063 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxoquinolin-3-ylidene)piperidine-1-carboxamide	KI	0.079 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide	KI	0.079 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4’-piperidine]-1’-carboxamide	KI	0.079 nM	US-10300056: CGRP receptor antagonists
tert-butyl 4-[(2S)-2-[[(2R)-3-(7-methyl-1H-indazol-5-yl)-2-[[4-(2-oxoquinolin-3-ylidene)piperidine-1-carbonyl]amino]propanoyl]amino]-3-oxo-3-(4-pyridin-4-ylpiperazin-1-yl)propyl]piperidine-1-carboxylate	KI	0.1 nM	US-10300056: CGRP receptor antagonists
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-(1-pentanoylpiperidin-4-yl)-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxoquinolin-3-ylidene)piperidine-1-carboxamide	KI	0.1 nM	US-10300056: CGRP receptor antagonists
3-[4-[(2S)-2-[[(2R)-3-(7-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-5-yl)-2-[[4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carbonyl]amino]propanoyl]amino]-3-oxo-3-(4-pyridin-4-ylpiperazin-1-yl)propyl]piperidin-1-yl]-3-oxopropanoate	KI	0.1 nM	US-10300056: CGRP receptor antagonists

ChEMBL bioactivities

234 potent at pChembl≥5 of 237 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	IC50	0.01	nM	CHEMBL4643006
10.96	Ki	0.011	nM	CHEMBL3893283
10.85	Ki	0.014	nM	CHEMBL2035984
10.82	Ki	0.015	nM	CHEMBL3981883
10.82	Ki	0.015	nM	ATOGEPANT
10.80	Ki	0.016	nM	CHEMBL2035985
10.77	Ki	0.017	nM	CHEMBL3914484
10.73	EC50	0.01862	nM	CAGRILINTIDE
10.70	Ki	0.02	nM	CHEMBL264010
10.70	Ki	0.02	nM	CHEMBL2371890
10.70	Ki	0.01995	nM	CHEMBL4638112
10.70	Ki	0.02	nM	CHEMBL4638635
10.70	Ki	0.02	nM	CHEMBL4638112
10.66	Ki	0.022	nM	MK3207
10.66	EC50	0.02188	nM	PRAMLINTIDE
10.60	Ki	0.02512	nM	CHEMBL4638938
10.60	Ki	0.025	nM	CHEMBL5813875
10.55	Ki	0.028	nM	CHEMBL2035982
10.52	IC50	0.03	nM	OLCEGEPANT
10.50	Ki	0.03162	nM	OLCEGEPANT
10.50	Ki	0.03162	nM	HTL-0022562
10.49	Ki	0.032	nM	HTL-0022562
10.40	Ki	0.04	nM	CHEMBL2035981
10.40	Ki	0.04	nM	CHEMBL3099918
10.40	Ki	0.03981	nM	CHEMBL4635521
10.40	Ki	0.04	nM	HTL-0022562
10.40	Ki	0.04	nM	CHEMBL5997296
10.40	Ki	0.04	nM	CHEMBL5747971
10.40	Ki	0.04	nM	CHEMBL4635521
10.35	IC50	0.045	nM	CHEMBL4647045
10.33	Ki	0.047	nM	CHEMBL2035983
10.30	Ki	0.05	nM	CHEMBL3099931
10.30	Ki	0.05	nM	CHEMBL3099925
10.26	Ki	0.055	nM	CHEMBL3968568
10.24	EC50	0.05754	nM	CHEMBL5567377
10.20	Ki	0.0631	nM	CHEMBL4640887
10.20	Ki	0.063	nM	CHEMBL5907647
10.20	Ki	0.063	nM	CHEMBL4640887
10.18	Ki	0.066	nM	CHEMBL3890519
10.17	Ki	0.067	nM	CHEMBL3944519
10.17	Ki	0.067	nM	UBROGEPANT
10.10	Ki	0.08	nM	CHEMBL3099920
10.10	Ki	0.07943	nM	CHEMBL4642755
10.10	Ki	0.07943	nM	CHEMBL4649523
10.10	Ki	0.079	nM	CHEMBL4642755
10.10	Ki	0.079	nM	CHEMBL4649523
10.10	Ki	0.079	nM	CHEMBL5916604
10.05	Ki	0.09	nM	CHEMBL3099916
10.03	Ki	0.093	nM	CHEMBL3971313
10.00	IC50	0.1	nM	OLCEGEPANT

PubChem BioAssay actives

141 with measured affinity, of 168 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3S)-3-[[(2S,3R)-2-[[(3S)-2-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	257877: Displacement of [3H-propionyl-K24] from halphaCGRP expressed in human neuroblastoma SK-N-MC cells	ki	<0.0001	uM
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	<0.0001	uM
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-2-oxospiro[1H-pyrido[2,3-d][1,3]oxazine-4,4’-piperidine]-1’-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	<0.0001	uM
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	<0.0001	uM
N-[(2S,5R,8R)-5-(2-cyanopropan-2-yl)-8-(4-fluoro-2-methylphenyl)-3-oxo-2,5,6,7-tetrahydro-1H-pyrrolizin-2-yl]-3-fluoro-5-methyl-4-[(3-methyl-6-oxo-1H-pyridazin-5-yl)oxy]benzamide	1657084: Inhibition of human CLR/RAMP1	ki	<0.0001	uM
N-[2-[(2S,5R)-2-(2-cyanopropan-2-yl)-5-(3-methylphenyl)pyrrolidin-1-yl]-2-oxoethyl]-3-methyl-4-[(3-methyl-6-oxo-1H-pyridazin-5-yl)methyl]benzamide	1657084: Inhibition of human CLR/RAMP1	ki	<0.0001	uM
N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	<0.0001	uM
4-[1-[5-[(2,6-dimethyl-4-pyridinyl)-methylamino]-4-[2-(2-methoxypropan-2-yl)-4-pyridinyl]-2-pyridinyl]piperidin-4-yl]-3,5-dihydro-1H-1,4-benzodiazepin-2-one	1657093: Inhibition of human CLR/RAMP1 by cAMP assay	ic50	<0.0001	uM
N-[(2-cyclobutyl-6-methyl-4-pyridinyl)methyl]-5-[(1R)-1-[(3R)-3-methyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-3-yl]ethyl]pyridine-2-carboxamide	1657084: Inhibition of human CLR/RAMP1	ki	<0.0001	uM
(4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	2085717: Agonist activity at human AMY1R complex of CTR/RAMP1 transduced in human HeLa cells by cAMP assay	ec50	<0.0001	uM
2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
(3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	257877: Displacement of [3H-propionyl-K24] from halphaCGRP expressed in human neuroblastoma SK-N-MC cells	ki	<0.0001	uM
(3S)-3-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-2-methylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	257877: Displacement of [3H-propionyl-K24] from halphaCGRP expressed in human neuroblastoma SK-N-MC cells	ki	<0.0001	uM
2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	<0.0001	uM
2-[(8R)-8-(4-chloro-3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
2-[(8R)-8-(4-chloro-3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
Pramlintide	2085717: Agonist activity at human AMY1R complex of CTR/RAMP1 transduced in human HeLa cells by cAMP assay	ec50	<0.0001	uM
2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	<0.0001	uM
Atogepant	1657091: Antagonist activity at human CLR/RAMP1	ki	<0.0001	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-2,2-dimethyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	<0.0001	uM
(3S)-3-[[(2S,3R)-2-[[(2S,4R)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid	257877: Displacement of [3H-propionyl-K24] from halphaCGRP expressed in human neuroblastoma SK-N-MC cells	ki	<0.0001	uM
N-[(3S,4R)-3-fluoro-1-(oxan-4-yl)piperidin-4-yl]-4-[[(4S)-4-methyl-2-oxopyrrolidin-1-yl]methyl]-3-[4-(6-propan-2-ylpyridazin-3-yl)phenoxy]benzamide	1657093: Inhibition of human CLR/RAMP1 by cAMP assay	ic50	<0.0001	uM
(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-4-[4-(2-oxo-4,5-dihydro-1H-1,3-benzodiazepin-3-yl)piperidin-1-yl]butane-1,4-dione	1657084: Inhibition of human CLR/RAMP1	ic50	0.0001	uM
N-[(2-cyclobutyl-6-methyl-4-pyridinyl)methyl]-4-[(1R)-1-[(3S)-3-methyl-2,5-dioxopyrrolidin-3-yl]ethyl]benzamide	1657084: Inhibition of human CLR/RAMP1	ki	0.0001	uM
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	0.0001	uM
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	0.0001	uM
N-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-1-[[(2S)-1-oxo-3-piperidin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	0.0001	uM
2-[(2S,6R)-2-(3-chlorophenyl)-6-fluoro-4-oxo-1,8-dioxa-3-azaspiro[4.5]decan-3-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[c]pyridine]-3’-yl]acetamide	1657084: Inhibition of human CLR/RAMP1	ki	0.0001	uM
N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-[[(2S)-1-oxo-3-pyridin-4-yl-1-(4-pyridin-4-ylpiperazin-1-yl)propan-2-yl]amino]propan-2-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide	1652728: Displacement of [3H]telcagepant from recombinant human CLR/RAMP1 expressed in Sf21 insect cell membranes measured after 60 mins by microbeta scintillation counting method	ki	0.0001	uM
(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoic acid	2085717: Agonist activity at human AMY1R complex of CTR/RAMP1 transduced in human HeLa cells by cAMP assay	ec50	0.0001	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]-1-(trifluoromethyl)cyclopropane-1-carboxamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
N-[(1R)-1-(3-fluoro-4-methylphenyl)ethyl]-2,2-dimethyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
Ubrogepant	1657091: Antagonist activity at human CLR/RAMP1	ki	0.0001	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-N-[(E)-3-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]prop-2-enyl]oxane-4-carboxamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-N-[3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-ynyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
2,2-dimethyl-N-[3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-ynyl]-N-[(1R)-1-phenylethyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-3-methyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]thiophene-2-carboxamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0001	uM
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-N-[(E)-3-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]prop-2-enyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
2,2-dimethyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]-N-[(1R)-1-phenylethyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,2-dimethyl-N-[3-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]prop-2-ynyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-2,2-dimethyl-N-[3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]propyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-2,2-dimethyl-N-[(E)-3-[(2R)-2’-oxospiro[1,3-dihydroindene-2,3’-1H-pyrrolo[2,3-b]pyridine]-5-yl]prop-2-enyl]propanamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
N-[(1R)-1-(3,5-difluorophenyl)ethyl]-1-methyl-N-[(E)-3-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]prop-2-enyl]imidazole-2-carboxamide	1061708: Displacement of [125I]-hCGRP from human CALCRL/RAMP1 expressed in HEK293 cell membranes	ki	0.0002	uM
N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxamide	1657084: Inhibition of human CLR/RAMP1	ic50	0.0002	uM
(1S,10R,20E)-12-methyl-10-[(7-methyl-1H-indazol-5-yl)methyl]-15,18-dioxa-5,9,12,24,26-pentazapentacyclo[20.5.2.11,4.13,7.025,28]hentriaconta-3,5,7(30),20,22(29),23,25(28)-heptaene-8,11,27-trione	1657084: Inhibition of human CLR/RAMP1	ki	0.0003	uM
[(2R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-(4-morpholin-4-ylpiperidin-1-yl)-1-oxopropan-2-yl] 4-(2-oxo-4,5-dihydro-1H-1,3-benzodiazepin-3-yl)piperidine-1-carboxylate	1657084: Inhibition of human CLR/RAMP1	ic50	0.0003	uM
2-[(8R)-8-(3,5-difluorophenyl)-8-ethyl-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(3S)-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-yl]acetamide	665599: Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	ki	0.0003	uM

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation, affects cotreatment	4
Benzo(a)pyrene	decreases methylation, increases expression	2
Cyclophosphamide	increases expression, affects cotreatment, affects response to substance	2
Dexamethasone	increases expression, affects cotreatment, decreases expression	2
Doxorubicin	increases expression, affects cotreatment, affects response to substance	2
Fluorouracil	affects cotreatment, affects response to substance, decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Valproic Acid	affects cotreatment, increases expression, decreases expression	2
pirinixic acid	affects binding, decreases expression, increases activity	1
deoxynivalenol	decreases expression	1
terbufos	increases methylation	1
trimellitic anhydride	decreases expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
nickel sulfate	increases expression	1
1-nitropyrene	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
MT19c compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Atrazine	decreases expression	1
Cadmium	increases expression	1
Calcitriol	increases expression, affects cotreatment	1

ChEMBL screening assays

43 unique, capped per target: 32 binding, 11 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2040005	Binding	Displacement of [125I]CGRP from human recombinant CALCRL/RAMP1 receptor expressed in HEK293 cells after 3 hrs	MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats. — Bioorg Med Chem Lett
CHEMBL4612975	Functional	Antagonist activity at human CGRP receptor in human SK-N-MC cells assessed as inhibition of CGRP-induced cAMP production preincubated for 30 mins followed by CGRP addition and measured after 30 mins by HTRF assay	Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2’-oxo-1’,2’-dihydrospiro[piperidine-4,4’-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine. — J Med Chem

Cellosaurus cell lines

11 cell lines: 5 spontaneously immortalized cell line, 4 transformed cell line, 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E4J2	Genomeditech HEK-293 H_CALCRL+RAMP1 Reporter	Transformed cell line	Female
CVCL_H398	CHO-K1/AMY1/CRE-Luc	Spontaneously immortalized cell line	Female
CVCL_H399	CHO-K1/AMY1/Galpha15	Spontaneously immortalized cell line	Female
CVCL_KA08	CHO-K1/Galpha15/AMY1	Spontaneously immortalized cell line	Female
CVCL_KU85	cAMP Hunter CHO-K1 CALCRL-RAMP1 Gs	Spontaneously immortalized cell line	Female
CVCL_KW48	PathHunter CHO-K1 CALCR-RAMP1 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_TI43	HAP1 RAMP1 (-) 1	Cancer cell line	Male
CVCL_TI44	HAP1 RAMP1 (-) 2	Cancer cell line	Male
CVCL_ZK45	GeneBLAzer CALCRL:RAMP1-CRE-bla FreeStyle 293F	Transformed cell line	Female
CVCL_ZK46	GeneBLAzer CALCRL:RAMP2-CRE-bla FreeStyle 293F	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.